CollabRx, Alacris Partner on Cancer Sequencing Project | GenomeWeb

NEW YORK (GenomeWeb News) – CollabRx, a San Francisco-based personalized cancer research services firm, today said that it has initiated a cancer sequencing project in collaboration with Alacris Pharmaceuticals.

The company said that the firms will work together on the TREAT 1000 project, which will sequence 1,000 genomes of people with cancer. It said that the project will "create a compendium of cancer genome information that will inform future research and treatment."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.